UnitedHealthcare and Quest Diagnostics have established a long-term strategic partnership as the two organizations focus on ways to create more personalized care recommendations and a simpler consumer experience for the more than 48 million people enrolled in UnitedHealthcare plans. Beginning Jan. 1, 2019, Quest will be participating as a national provider of laboratory services for all UnitedHealthcare plan participantsUnder the partnership, UnitedHealthcare and Quest will use real-time data
Read More
Quest Diagnostics
Quest Diagnostics Acquires Cleveland HeartLab to Establish Cardiometabolic COE
Quest Diagnostics has signed a definitive agreement to acquire Cleveland HeartLab, a provider of innovative diagnostic services for managing cardiovascular disease. A spin-off of Cleveland Clinic, Cleveland HeartLab has created a specialized approach to identifying risk of heart disease, based in part on science published in more than 100 peer reviewed journals. As part of the acquisition, Cleveland HeartLab will serve as the base for Quest's first national center of excellence in
Read More
Quest Diagnostics Completes Acquisition of Med Fusion
Quest Diagnostics has announced the completed its acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company’s first national center of excellence in precision diagnostics for oncology. For patients with cancer, precision diagnostics, such as genomic sequencing of a tumor's DNA, may help a physician select a therapy or clinical trial and monitor response.In
Read More
IBM Watson, Quest Diagnostics Partner to Offer Gene Sequencing Service
IBM Watson is teaming up with Quest Diagnostics to launch Watson Genomics from Quest Diagnostics, a gene sequencing and Watson diagnostic analysis service to help oncologists deliver precision medicine to their patients. Together with Memorial Sloan Kettering Cancer Center (MSK), the service will provide a personalized tumor analysis of a patient’s sequenced genomic tumor that is supported by clinical evidence. As part of the precision medicine partnership, The Broad Institute of MIT and Harvard
Read More
Leidos Closes $5B Lockheed Martin Acquisition, Appoints 3 New Directors
Leidos has announced the successful $5B acquisition of Lockheed Martin's Information Systems & Global Solutions (IS&GS) business in a Reverse Morris Trust transaction. The division has about $5 billion in sales and more than 16,000 employees globally, IS&GS has been a leading government services provider for more than 20 years. Lockheed states the move will allow them to focus more on its core aerospace and defense operations.The Leidos Board of Directors also announced the election
Read More
